Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 15Uterine Cervical Neoplasms 7Endometrial Neoplasms 7Fallopian Tube Neoplasms 6Parkinson Disease 4, Autosomal Dominant Lewy Body 5Carcinoma, Renal Cell 4Carcinoma, Ovarian Epithelial 4Pancreatic Neoplasms 3Melanoma 3Colorectal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 3Urinary Bladder Neoplasms 2Thyroid Neoplasms 2Small Cell Lung Carcinoma 2Sarcoma 2Salivary Gland Neoplasms 2Neuroendocrine Tumors 2Lung Neoplasms 2Head and Neck Neoplasms 2Esophageal Neoplasms 2Cholangiocarcinoma 2Carcinoma, Hepatocellular 2Brain Neoplasms 2Vulvar Neoplasms 1Uterine Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Cancer, Papillary 1Testicular Neoplasms 1Teratoma 1

Interventions

Taxes 1Paclitaxel 1Immunoglobulin G 1Disulfides 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × Brenner Tumor × Gynecologic × Clear all
NCT00262847 2019-07-23

Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

National Cancer Institute (NCI)

Phase 3 Completed
1,873 enrolled 17 charts 1 FDA
Gynecologic

Brenner Tumor, Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡